In the Indian market cheaper medicines like cancer, heart and sugar are coming. Due to cheaper medicines, their patients will get much relief. It is worth mentioning that in the next 3 to 5 years, the patent period of many medicines that are used to treat heart diseases, diabetes and cancer in the Indian market is going to end. After this, the domestic drug companies will present the generic version of these drugs, which is expected to reduce their prices. Pharmaceutical industry experts say that the cost of cancer medicines can be the worst. It will depend on how many companies are approved for drugs after the end of the patent period. However, the annual compounding of molecules with patents like Epixaben 381 in the last 5 years 9 percent. Its patent is near Pfizer and it sells it to Elixvis brand. The sale of drug glyptines, which is being used for the treatment of diabetes, is growing at 40 percent.
There is a lot of repercussion in this category because more than 160 brands want to capture the country's diabetic drug market more than 100 billion rupees. The period of the patent of the four important drugs of the Gliptins group, sitagliptin, linalagliptin, weldagliptin and xxagliptin, is expected to end in the next 5 years. Their total market in the country is 7.3 billion rupees. Only about 20 pharmaceutical companies have been granted licenses to make them. The country's gliptins market is worth 25 billion rupees and major pharmaceutical companies have joined hands with international companies to sell them. In January, Cipla joined hands with Swiss company Novartis for the sale of Weldagliptin. Likewise, Alchem signed a deal with avocaliptin company Dong A for South Korea's company. Novartis for Weldagliptin already has USV Pharma, Has compromised with Mkure and Abbott. An official of the leading pharmaceutical company told that his company has prepared the generic version of the weldagliptin and it will be removed in the Indian market once the patent period is over.